Zydus Lifesciences logo

Zydus Lifesciences

India (Ahmedabad) • Manufacturer

Zydus Lifesciences is a manufacturer of peptides based in India (Ahmedabad). Direct manufacturer. Founded 1952. Key products include peptide APIs, generic APIs.

FDA warning letter
The U.S. FDA sent Zydus Lifesciences a warning letter dated August 29, 2024 (CGMP, finished pharmaceuticals; Jarod, Gujarat facility, not a peptide API site). Read the letter on fda.gov. A warning letter is not a court ruling, and companies can respond to it; check fda.gov for any close-out letter.
FDA warning letter
The U.S. FDA sent Zydus Lifesciences a warning letter dated June 2, 2026 (CGMP, finished pharmaceuticals; Baddi, Himachal Pradesh facility, not a peptide API site). Read the letter on fda.gov. A warning letter is not a court ruling, and companies can respond to it; check fda.gov for any close-out letter.
Official WebsiteReport Discrepancy
Verification Summary
ConfidenceMedium
Business TypeManufacturer
ModelManufacturer
RegionAsia
Founded1952
Verification status based on publicly available information and supplier-provided materials.

Listing reviewed October 2026.

Is this your company? Claim this listing to update your info and get a verified badge.Claim This Listing

About Zydus Lifesciences

Indian pharmaceutical group (formerly Cadila Healthcare) making generics, specialty medicines, biologics and APIs. Its semaglutide API Drug Master File is filed by the group company Zydus Worldwide DMCC.

Directory assessment: Zydus Lifesciences is listed as a manufacturer in the peptide supply chain, serving Asia markets from India (Ahmedabad). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.

Products & Categories
Products (4)
peptide APIsgeneric APIsgeneric formulationsbiologics
Capabilities
Peptide APIsBiologics
Categories
peptideManufacturingpharmaceutical
Quality & Logistics
In-House Production
Manufacturing & regulatory
US Drug Master Files
  • Semaglutide: DMF 36389 (Type II, active), submitted 2021-10-15

DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-15.

Listing Sources

Related Suppliers

WuXi AppTec (TIDES)
China • CDMO
GL Biochem (Shanghai)
China • Bulk Wholesale
Zhejiang Peptides (ZPC)
China • Bulk Wholesale
Hongzi Peptide
China • Bulk Wholesale